Serono and Syntonix Sign Worldwide Agreement to Develop and Commercialize an Inhaleable Interferon-Beta Therapy for Multiple Sclerosis

News | 03. 31. 2005

Syntonix Pharmaceuticals

Serono (virt-x: SEO and NYSE: SRA) and Syntonix Pharmaceuticals Inc. announced today that they have entered into an agreement under which Serono has licensed worldwide exclusive rights to Syntonix’ TransceptorTM and SynFusionTM technologies for the development and commercialization of interferon-beta:Fc products.